Introduction: Antipsychotic-induced weight-gain (AIWG) is a very important, yet often
neglected side-effect in the treatment with first and second generation antipsychotics. AIWG …

Second generation antipsychotics (SGAs) are effective options in the treatment of
schizophrenia and mood disorders, each with characteristic efficacy and safety features. In …

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published
treatment guidelines for bipolar disorder in 2005, along with international commentaries and …

Objective: The authors evaluated the efficacy, safety, and tolerability of cariprazine, an
atypical antipsychotic candidate, in adult patients with acute bipolar I depression. Method …

Objective: Cariprazine, a dopamine D3/D2 and 5-HT1A receptor partial agonist, was found
to be effective in treating bipolar I depression in a previous phase 2 study. This phase 3 …

Objectives: Although clinically highly relevant, the recognition and treatment of bipolar mixed
states has played only an underpart in recent guidelines. This WFSBP guideline has been …

Background: Brexpiprazole and cariprazine are the latest US Food and Drug Administration
approved atypical antipsychotics available in the United States. Both function as partial …

Background: The current paper includes a systematic search of the literature, a detailed
presentation of the results, and a grading of treatment options in terms of efficacy and …

Dopamine (DA), as one of the major neurotransmitters in the central nervous system (CNS)
and periphery, exerts its actions through five types of receptors which belong to two major …

Objective To assess the efficacy, safety, and tolerability of cariprazine in the treatment of the
depressed phase of bipolar I disorder in adults (NCT02670538). Methods In this phase 3 …